Xeno Transplants Corporation (XENO)
- Previous Close
0.0001 - Open
0.0001 - Bid --
- Ask --
- Day's Range
0.0001 - 0.0001 - 52 Week Range
0.0001 - 0.0001 - Volume
22,500 - Avg. Volume
357 - Market Cap (intraday)
64,582 - Beta (5Y Monthly) -26.79
- PE Ratio (TTM)
-- - EPS (TTM)
-0.0000 - Earnings Date --
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
--
Xeno Transplants Corporation operates as a bio-technology research and development company. The company, through a license agreement with Massachusetts General Hospital, intends to develop, manufacture, distribute, and use products and processes for public use with regard to xenotransplantation. The Xenotransplantation is intended to address the problems arising from the limited supply of available human cells, tissues, and organs for transplantation by developing technologies to permit the transplantation of cells, tissues, and organs from other species into humans, such as swine. Xeno Transplants Corporation was incorporated in 2004 and is based in Brookline, Massachusetts.
Related News
Performance Overview: XENO
Trailing total returns as of 4/24/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: XENO
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: XENO
Valuation Measures
Market Cap
--
Enterprise Value
--
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
--
Price/Book (mrq)
--
Enterprise Value/Revenue
--
Enterprise Value/EBITDA
-0.72
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
--
Return on Equity (ttm)
--
Revenue (ttm)
--
Net Income Avi to Common (ttm)
-256.37k
Diluted EPS (ttm)
-0.0000
Balance Sheet and Cash Flow
Total Cash (mrq)
261
Total Debt/Equity (mrq)
1,509.20%
Levered Free Cash Flow (ttm)
--
Company Insights: XENO
XENO does not have Company Insights